Nano-Targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0364
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future

Women's Health
Medicine
2015English

Triple-Negative Breast Cancer

2018English

Development of Biodegradable PLGA Nanoparticles Surface Engineered With Hyaluronic Acid for Targeted Delivery of Paclitaxel to Triple Negative Breast Cancer Cells

Materials Science and Engineering C
Mechanics of MaterialsMaterials ScienceCondensed Matter PhysicsMechanical Engineering
2017English

Platinum-Based Therapy for Triple-Negative Breast Cancer Treatment: A Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Delivery of Anti-miRNA for Triple Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting to Stem Cell Marker CD133

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2019English

212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Targeted Delivery for Breast Cancer Therapy: The History of Nanoparticle-Albumin-Bound Paclitaxel

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy